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Résumé 
La sclérose systémique (ScS) est une maladie auto-immune dévastatrice d'étiologie 
inconnue. Le dysfonctionnement immunitaire, la fibrose et la vasculopathie sont les trois 
principales caractéristiques de cette maladie. Une récente étude a révélé un nouveau lien 
entre l'auto-immunité et la fibrose, par la présence d'auto-anticorps stimulant le récepteur 
du facteur de croissance dérivé des plaquettes (PDGFR) des fibroblastes. Ces auto-
anticorps sont capables de stimuler les espèces réactives de l'oxygène et d’activer la kinase 
régulée par un signal extracellulaire (ERK1/2). L’hypothèse que nous formulons est que  
les cellules musculaires lisses vasculaires (VSMCs) exprimant conjointement les PDGFR,  
répondront elles  aussi aux autoanticorps anti-PDGF-R. Le travail présenté ici vise à valider 
la présence d'auto-anticorps PDGFR dans les sérums de patients ScS, et à caractériser 
ensuite la réponse de VSMCs exposées à de l'immunoglobuline G (IgG) de ces sérums, en 
mesurant l’activation des cascades de signalisation spécifiques, ainsi que l'induction des 
gènes impliqués dans la réponse fibrotique.  
Nos résultats démontrent la présence d'une fraction IgG stimulant une réponse 
phénotypique dans les cultures de VSMCs. Notamment, d’importantes régulations positive 
et négative des gènes pro-fibrotiques tgfb1 et tgfb2 respectivement, ont été observées dans 
les VSMCs exposées à des fractions de ScS-IgG. Les fractions de IgG positives pour 
l'activation de ERK étaient présentes dans la plupart, mais pas dans tous les échantillons de 
SSc (68%, 19/28), et moins présentes dans les contrôles 27% (11/3). Bien que, les fractions 
de SSc-IgG ont pu considérablement immunoprécipiter le PDGFR, l'utilisation d'un 
inhibiteur spécifique des récepteurs au PDGF (AG1296), n'a pas inhibé l'activation de ERK 
médiée par les fractions de SSc-IgG. Globalement, nos résultats indiquent la présence 
d'autoanticorps stimulants avec activité pro-fibrotique dans les sérums des patients ScS. 
Des travaux sont en cours pour identifier l'entité moléculaire responsable de la réponse 
d’IgG observée dans les cultures de VSMCs. 
Mots-clés: Sclérose systémique, CMLV, PDGFR, auto-anticorps 
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Abstract 
Systemic Sclerosis (SSc) is a devastating autoimmune disease of unknown etiology. 
Immune dysfunction, fibrosis and vasculopathy are the three major features of the disease; 
however, the interactions between these components are poorly understood. A novel link 
between autoimmunity and fibrosis has been proposed by the presence of stimulatory 
autoantibodies to the platelet-derived growth factor receptor (PDGFR) on fibroblasts. These 
autoantibodies were capable of stimulating reactive oxygen species and subsequent 
activation of ERK1/2. If the anti-PDGFR autoantibodies are present in the systemic 
circulation of SSc patients, they will most certainly encounter vascular smooth muscle cells 
(VSMCs). The latter are known to express the PDGFR and response to PDGF, which is a 
known phenotypic modulator of VSMCs. The work presented here seeks to readdress the 
presence of stimulatory anti-PDGFR autoantibodies in serum derived from SSc-patients 
and to characterize the effects of SSc-IgG on VSMCs by measuring the activation of 
specific signaling cascades and the induction of genes involved in fibrotic responses.  
Our results demonstrate the presence of an IgG fraction stimulating a phenotypic 
response in cultured VSMCs. Notably, a significant up-regulation of the pro-fibrotic gene 
tgfb1 and a significant down-regulation of the anti-fibrotic gene tgfb2 were observed in 
VSMC exposed to SSc-IgG fractions. Positive IgG fractions for ERK activation were 
present in most, but not all, SSc samples (68%, 19/28), and they were less present in 
controls (27%) (3/11). Although, the SSc-IgG fractions were able to significantly 
immunoprecipitate the PDGFR, the use of a selective PDGFR inhibitor, AG1296, did not 
inhibit the activation of ERK mediated by SSc-IgG fractions. Altogether, our findings 
suggest the presence of stimulatory autoantibodies with profibrotic activity in serum 
derived form SSc patients. Work is in progress to identify the molecular entity responsible 
for the IgG response observed in cultured VSMCs.  
Keywords: Systemic Sclerosis, vascular smooth muscle cells, PDGFR, autoantibodies  
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Chapter 1: Introduction 
1.1 Immune system and Tolerance 
The immune system plays a major role in the protection of our body against 
infectious disease caused by bacteria, viruses or any other pathogen. This protection is 
achieved through two main immune responses: innate and acquired. The innate response 
provides the first line defence against many foreign substances. It consists of specialized 
cells and nonspecific molecules that respond quickly to the stimuli. However, the innate 
response is not effective against all pathogens and it lacks the ability to provide specific 
protective immunity against re-infection. The acquired response, in turns, provides a more 
diverse defence with much slower respond. It gains the advantage of targeting specific 
pathogen and generates a memory response protecting against re-infection with the same 
pathogen. The effectors cells involved in the adaptive immune response are acquired B and 
T cells. Each one of them bearing specific receptors: the B cell receptor (BCR) and those of 
T cells (TCR). These receptors can recognize a multitude of different antigens providing 
protection against most pathogens that we will encounter during life. The strong affinity 
interaction between a foreign molecule and its specific receptor induces the activation of 
these cells and causes their clonal expansion. These lymphocytes become specific and then 
migrate into the infected tissue causing inflammation and contributing to the elimination of 
the source of foreign antigen. Once this is done, the majority of specific lymphocytes 
disappear and the inflammation will subside (Janeway, 1997; Parham, 2009; Ranque, 
2010).  
Some developing B and T cells may carry receptor that bind to normal components 
of the human body, which is called self-antigen. To prevent this, several mechanisms have 
been evolved early in the foetal stage of life to induce a state of immunological tolerance 
towards self-antigen. During T cells development in the thymus, the cells are subjected to 
negative selection process where highly self-reactive cells are eliminated by apoptosis, 
macrophages and dendritic cells. Another mechanism is the absence of co-stimulatory 
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signals of antigen-presenting cells (APC); T cells become anergic and cannot induce 
immunity responses. There are also regulatory T cells that allow the suppression of auto-
reactive T cells. 
The same mechanisms of self tolerance are present in bone marrow during the 
maturation of B cells that are responsible for humeral immunity (antibodies production) 
(Janeway, 1997; Parham, 2009). These mechanisms of tolerance could be altered causing 
autoimmune diseases. 
1.1.1 Autoimmune disease 
Autoimmune diseases are caused by unwanted adaptive immune responses. They 
represent failures of the mechanisms that maintain self-tolerance. They can be caused by 
antibodies (Abs) that perturb a normal physiological function or by inflammatory T cells 
that damage healthy cells or tissue at a rate beyond the capacity of the body to repair. Some 
autoimmune disease are directed against antigens of one particular organ or tissue and are 
known as organ-specific or tissue-specific autoimmune disease, such as insulin-dependent 
diabetes. In contrast, others are directed against components common to all cells and are 
known as systemic autoimmune disease, such as systemic sclerosis (SSc) (Parham, 2009). 
1.2 Systemic Sclerosis 
SSc is a rare autoimmune connective tissue disease of unknown cause. Indeed, 
genetic and environmental factors could be the origin of the disease, but this still uncertain. 
SSc is highly heterogeneous and multisystemic in its clinical manifestations. The main 
organs affected are the skin, lungs, kidneys, gastrointestinal tract and heart. 
The principle features of the disease are extensive fibrosis, vascular alteration and 
autoantibodies (autoAbs) against various cellular antigens (Gabrielli, 2009). The interaction 
between these features is complicated and not completely understood. However, researches 
and clinical symptoms suggest that vascular injury triggers the disease and leads to 
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inflammation and autoimmunity. Different Cytokines and autoAbs are involved in the 
disease. Cytokines production, caused by inflammatory cells, may stimulate fibroblast 
differentiation into myofibroblast. The latter will induce overproduction of collagen and 
other extracellular matrix (ECM) proteins leading to fibrosis (Varga, 2007). 
1.2.1 Epidemiology and Demographics 
In all epidemiology studies, SSc is reported to occur more frequently in women than 
in men with an overall ratio of approximately 3:1 (Chifflot, 2008). SSc onset occurs most 
likely in fifth decade and rarely in childhood and extreme elderly (Ansell, 1976; Czirjak, 
1992; Ranque, 2010). Some races are more vulnerable to the disease than others are. For 
example, Choctaw Native Americans living in Oklahoma reported one of the highest SSc 
prevalence (Arnett, 1996). In addition, black Americans showed a higher age-specific 
incidence rate than white ones (Clements, 2004; Ranque, 2010). 
SSc has a worldwide distribution (Silman, 1996).  Its population have been 
characterized in patients from the United States, France, Japan, Australia and others 
(Scussel-Lonzetti, 2002). The reported incidence rates and prevalence show a wide 
variation among different countries. According to the epidemiological international studies 
of SSc, its incidence ranges from 2.7 to 23 new cases per million per year (Clements, 
2004). While, the prevalence is estimated between 31 to 1470 cases per million and appears 
to be higher in North America and Australia as compared to Europe and Japan (Clements, 
2004; Koopman, 2004; Ranque, 2010). 
In Quebec, the prevalence rate of 443 cases per million was calculated and it 
differed greatly between sexes and ages. Prevalence was higher for older individuals and 
females, with a female to male ratio of 6:1 (Scussel-Lonzetti, 2002; Bernatsky, 2009). 
Studies have also examined the patients’ mortality and survival. Although deaths 
are more common in people diagnosed with SSc than in healthy individuals (Scussel-
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Lonzetti, 2002), the 10-year cumulative survival after the physician diagnosis had improved 
from 54%  in 1970 to 82%  nowadays (Ranque, 2010). 
1.2.2 Diagnosis and Classification 
In 1980, the American College of Rheumatology (ACR) has defined diagnostic 
criteria for SSc that is 97 % sensitive and 98 % specific for the disease. The patient should 
fulfill the major criterion or two of the three minor criteria in order to be diagnosed with 
SSc. The major criterion is skin thickening proximal to the metacarpophalangeal joints. The 
minor criteria are having sclerodactyly (localized thickening and tightness in fingers or toes 
skin), digital pitting scars or bilateral basilar pulmonary fibrosis (Clements, 2004; 
Koopman, 2004).  
SSc is a practically challenging problem for classification because it includes a very 
broad spectrum disease. The most widely accepted classification is the one based on the 
extent of skin involvement. Patients are classified into two main groups: limited SSc (lSSc) 
with skin involvement essentially limited to the hands and face; and diffuse SSc (dSSc) 
with skin involvement proximal to the elbows and knees. In patients with lSSc, visceral 
involvement is rare, with the exception of patients in whom pulmonary arterial 
hypertension (PAH), interstitial lung disease and/or bowel involvement eventually develop. 
Patients with dSSc experience visceral involvement including renal crisis, interstitial lung 
disease, PAH, heart and gastrointestinal tract involvement (Koopman, 2004; Ranque, 
2010). 
Classification based on serum autoantibodies is also characterized. Two major 
serum autoAbs in SSc patients have been recognized since 1980: anticentromere (ACA) 
and antitopoimerase I (anti-topo I) Abs. The latter is specific to SSc, and two-thirds of 
patients with this autoantibody have dSSc and pulmonary interstitial fibrosis. ACA is 
present primarily in patient with lSSc (Clements, 2004).  
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1.2.3 Etiology 
The etiology of SSc is unknown but it seems to result from multifactorial processes 
such as alteration of immune system, genetics and environmental factors (Chifflot, 2008). 
Many substances have been implicated in the pathogenesis of this disease e.g. organic 
solvents, silica dust, vinyl chloride and silicone breast implants. Studies on these substances 
failed to establish a strong association between occurrence of SSc and exposure to any 
particular agents (Chifflot, 2008). 
In addition, genetic factor had been investigated. Several studies found that a family 
history or a first degree relative has a significant risk factor for the disease. However, the 
absolute risk remains very low around 1% (Arnett, 2001; Zhou, 2001; Roberts-Thomson, 
2006). Moreover, genetic, familial, and twin studies suggest that SSc occurs in genetically 
susceptible individuals (Feghali-Bostwick, 2005). 
Overall, the pathogenesis of SSc appears to be influenced with both environmental 
and genetic factors (Ranque, 2010).  
1.2.4 Clinical Manifestation 
1.2.4.1 Fibrosis 
Fibrosis is the pathological hallmark of SSc. Uncontrolled production of collagens 
and other ECM proteins by fibroblast residing in the skin, lungs and other vital organs leads 
to excess connective tissue accumulation. Over time, progressive build-up of connective 
tissue disrupts the normal tissue architecture of affected organs, causing their dysfunction 
and eventual failure. Thus, the fibrotic process contributes significantly to the morbidity 
and mortality of SSc (Varga, 2008; Ranque, 2010). 
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1.2.4.2 SSc Effect on the Skin 
The skin is an organ severely affected in SSc. There are three evolving phases of 
skin thickening in individuals with SSc. First, the edematous phase, the patients complain 
of swollen fingers and edema in the dorsum of the hands, forearms, legs, feet and face. 
After that, the edema is gradually replaced by thickened tight skin which is called the 
indurative phase. During this phase, the dermis is markedly thickened and the epidermis is 
thinned. This leads to hair loss on the extremities, decreased sweating and mobility 
impairment of muscles, tendons and joints, which is called sclerodactyly. With time, the 
thickening of the skin freezes facial expression. Of note, this phase is rapid in dSSc, while 
it takes 15 to 20 years in lSSc form. Finally, in the atrophic phase, the thickened dermis 
softens and returns to a normal thickness. In addition, telangiectasias, which are red skin 
lesions caused by dilated blood vessels, increase in number and become the dominant 
visual feature for the patient.  
In addition to fibrosis, SSc can cause ulceration of the skin fingers caused by 
ischemia. In some patients, it degenerates into necrosis. The fingers become painful and the 
patients have a poor quality of life. Calcium deposits (calcinosis) are also observed in 
patients with lSSc (Clements, 2004). 
1.2.4.3 SSc Effect on the Lung 
Pulmonary fibrosis (PF) is a common complication of SSc. 25 to 90% of patients 
suffering from SSc had PF. It is often severe and can cause death. PF can be found in both 
forms of the disease, but it is much more frequent in patients with the diffuse form. A 
significant loss of lung volume is seen in people with PF. Moreover, the macrophages and 
lymphocytes can be found in inter-alveolar space and inflammation of the lung is noticed.  
Pulmonary arterial hypertension (PAH) is another severe complication observed in 
patients with SSc. It is a destructive vascular complication in the lungs with abrupt onset 
and often lethal outcome. PAH is caused by a thickening of pulmonary arteries. This 
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generates a decrease in diffusing capacity for carbon monoxide (DLCO) and forced vital 
capacity (FVC) that corresponds to the forced expiration (Clements, 2004).  
The thickening of the pulmonary arteries is a result of several vascular changes that 
affect all three layers (i.e., intima, media and adventitia) of the pulmonary vessel. Each cell 
type (endothelial, smooth muscle and fibroblast) in the pulmonary vascular wall plays a 
specific role in the pathogenesis (Humbert, 2008). Endothelial cell (EC) injury is the 
critical early event in SSc-associated pulmonary vascular disease. It leads to alterations in 
endothelial function with increased production of vasoconstrictor mediators, such as 
endothelin-1 (ET-1), and decreased synthesis of prostacyclin and nitric oxide (NO) (Varga, 
2002). In normal individuals, vasoactive molecules produced from EC adapt the pulmonary 
vascular smooth muscle cells (VSMCs) tone to the actual needs of the organism and keep 
the smooth muscle in a state of relaxation. In PAH, the imbalanced productions of 
vasoactive mediators lead to increased pulmonary vascular reactivity and abnormal 
vasoconstriction (Muller-Ladner, 2009). 
Beside that, endothelial dysfunction triggers two cascades that contribute to the 
pulmonary artery thickening; vascular remodeling, and in situ thrombus formation (Varga, 
2002). Besides its vasoconstrictive effects, ET-1 also promotes VSMCs proliferation. 
Hypertrophy of the intima and medial layers of pulmonary vessels due to VSMCs growth 
and proliferation causes significant luminal narrowing (Weissberg, 1990; Weber, 1994). 
Inflammation also plays a role in SSc-PAH, as patients have perivascular inflammatory cell 
infiltrates, such as T and B cells, and macrophages (Le Pavec, 2010). The immune response 
activation results in the production of autoAbs and fibrosis. This fibrotic response leads to 
adventitial fibrosis, furthering the vascular remodeling (Norton, 1970). This process can 
even progress to cause an almost complete occlusion of the pulmonary arterioles. Over all, 
vasoconstrion and luminal narrowing lead to elevated pulmonary vascular resistance and 
increase pulmonary artery pressure leading to SSc-PAH. (Figure 1, page 8, shows the 
pulmonary vascular remodeling in SSc-PAH). 
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Figure 1: Pulmonary vascular remodeling in SSc-PAH. Modified from (Le Pavec, 
2010). 
1.2.4.4 SSc effect on other organs 
In addition to skin and lungs, the heart, kidneys and gastrointestinal tract are 
subjected to fibrosis in SSc. Myocardial fibrosis is a hallmark of cardiac SSc. Cardiac 
involvement is found in up to 80% of patients who have SSc. In the SSc heart, significant 
interstitial and perivascular fibrosis are found, this will contribute to diastolic dysfunction 
as the disease progress. In addition, the heart vessels may be sclerotic and thus lead to 
dyspnea, palpitations and arrhythmia (Clements, 2004; Varga, 2008). 
In the kidneys of patients with SSc, the glomeruli shrunk leading to chronic renal 
ischemia and other ischemic changes. Pathological changes can also occur in the 
Vascular remodeling 
EC apoptosis, activation and/or  
proliferation 
SMCs hyperplasia/hypertrophy 
Inflammatory cell recruitment, cell 
proliferation and fibrosis 
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gastrointestinal tract of SSc patients at any level from the mouth to the rectum. The 
esophagus is virtually always affected with fibrosis. Replacement of the normal intestinal 
architecture results in disordered peristaltic activity, gastroesophageal reflux and small 
bowel dysmotility, pseudo-obstruction, and bacterial overgrowth (Clements, 2004; Varga, 
2008).  
Musculoskeletal involvement is evident in 1/3 to 1/2 of SSc patients and it is 
expressed as muscle weakness. In addition, Carpel tunnel syndrome is documented in SSc 
patients due to the fibrotic thickening of the tendon sheaths (Panayiotis, 2001). 
Other clinical manifestations are Raynaud's phenomenon which affects almost all 
SSc patients (Panayiotis, 2001). It is caused by a vasoconstriction of arterioles after 
exposure to cold causing the skin to become pale, waxy-white or purple (Clements, 2004). 
Of note, PAH and Raynaud’s syndrome share numerous similarities, not only on a clinical 
level with a substantial number of patients suffering both from Raynaud’s syndrome and 
PAH, but also on a molecular level as both entities are characterized by endothelial 
dysfunction with reduced NO release and increased plasma levels of  ET-1 (Muller-Ladner, 
2009).  
1.2.5 Animal models  
The search for the ultimate etiology of SSc fibrosis, the problem of disease 
classification and the fact that the initial stage is generally not accessible in humans 
highlight the need for appropriate animal models in SSc. Animal models in SSc can be 
divided into two groups. In the first group, the pathologic phenotype is the result of a 
genetic mutation. These models are associated with the spontaneous development of SSc-
like features. In the second group, the pathologic alterations are induced in normal animals 
by manipulation of their immune system or by administration of exogenous substances 
(Rogai, 2008; Yamamoto, 2009). 
  
 
10
Examples of the first group are tight skin 1 (TSK1) and University of California at 
Davis line of chicken (UCD-200). First, in TSK1, the most striking features are: the 
presence of thickened fibrotic skin that is firmly bound to the subcutaneous and deep 
muscular tissue, and SSc-like activation of the TSK-1 fibroblasts. However, dermal 
sclerosis and vascular phenotype are not recognized, and additional non-SSc pathologies 
are noticed, including emphysema and kyphosis (Yamamoto, 2009; Beyer, 2010). Second, 
the UCD-200, this model of chickens spontaneously develops vascular damage, 
mononuclear cell infiltrates, fibrosis of the skin and internal organs, and polyarthritis. 
Thereby, it almost manifests the entire pathologic spectrum of SSc; it has a very early onset 
and shows rapid progression. Thus, UCD-200 provides a unique opportunity to study the 
earliest profibrotic events of SSc since the disease course closely resembles that of human 
SSc (Yamamoto, 2009; Beyer, 2010). 
Examples of the second group are sclerodermatous Graft-versus-host disease (Scl-
GVHD) and bleomycin-induced SSc. First, the Scl-GVHD mice exhibit skin thickening and 
pulmonary fibrosis after bone marrow transplantation. Thereby, systemic disease 
manifestations exist, but the sophisticated technical skills and difficulties in handling the 
immunocompromised mice are a major limitation (Yamamoto, 2009; Beyer, 2010). Second, 
the bleomycin-induced SSc is induced by the repeated injections of bleomycin into the back 
skins in mice. Histopathological examination revealed definite dermal sclerosis, which 
mimicked the histological features of human SSc; however, no major systemic 
manifestations are involved (Yamamoto, 2009; Beyer, 2010).  
1.3 Pathogenesis of Systemic Sclerosis 
Although the hallmark of SSc is widespread connective tissue fibrosis, the earliest 
and most frequent manifestations include blood vessel and immunological abnormalities. In 
recent years, research on SSc has evolved to provide a better understanding of the 
interdependence of the three major systems—namely, the vascular system, the immune 
system and the connective tissue involved in the disease (Hunzelmann, 2009). As studies 
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showed, vascular damage and leukocyte accumulation generate the molecular cues that 
control the profiles of soluble mediators. The latter regulate the aberrant behaviour of 
mesenchymal cells within connective tissues. Where, the dysregulated expression of these 
molecules and cells differentiation will contribute to the persistent fibrogenic response in 
SSc (Abraham, 2005). (Figure 2, page 12, shows a model of SSc pathogenesis). Herein we 
will discuss the role of each of these systems in SSc. 
1.3.1 Vascular System 
Vascular injury is the earliest, if not the primary, events in the pathogenesis of SSC. 
Histopathological evidence of vascular damage is present before fibrosis, and clinical 
manifestation such as Raynaud’s phenomenon precede other disease manifestation 
(Kahaleh, 2004; Varga, 2007). Additional manifestations of SSc-associated vasculopathy 
include PAH, renal crisis and cutaneous telangiectasia (Clements, 2004). The most 
important cells involved in SSc vasculopathy are: endothelial cells (EC), vascular smooth 
muscle cells (VSMCs) and Pericytes. 
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Figure 2: A model of SSc pathogenesis. Modified from (Robitaille, 2009). 
It shows interaction between vascular system (EC & VSMCs), Immune system (B & T 
cells) and connective tissue (fibroblast & myofibroblasts) in SSc.  
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1.3.1.1 Endothelial Cells  
The endothelium is a metabolically active tissue that under normal circumstances 
regulates regional blood flow, transportation of nutrients and migrations of blood cells 
while maintaining an antithrombotic lining in the vasculature (Cines, 1998). These 
important biologic functions are achieved through the production of a complex array of 
molecules including vasodilators (e.g. NO and prostacyclin), vasoconstrictors (e.g. ET-1), 
platelet-activating factor and cell adhesion molecules (e.g., selectins and integrins) 
(Schachna, 2002). 
In SSc, the homeostatic function of endothelium is disrupted by EC activation 
and/or injury (Figure 2, page 12, step 1). The exact cause of EC activation or injury is 
unknown (Schachna, 2002). Moreover, endothelial regression in SSc suggests increase in 
EC apoptosis (Chen, 2003). The proposed mechanisms of endothelial apoptosis include 
damage by reactive oxygen specious (ROS) generated during ischemia/reperfusion, anti-
endothelial Abs, inflammatory cytokines, abnormal ROS: NO ratios, vasculotropic viruses, 
altered basement membranes and decreased CD34 (Chen, 2003; Varga, 2007).  
The loss of viable EC leads to loss of protective and vasodilating cytokines e.g. NO. 
The loss of vascular prostacycline favours platelet aggregation and in situ thrombosis 
(Clements, 2004). In addition, the vasoconstrictive mediator such as ET1 predominates and 
promotes leukocytes adhesion as well as intimal proliferation and fibrosblasts activation 
(Clements, 2004; Varga, 2007; Gabrielli, 2009). In addition, damage to the endothelium 
induces the release of proinflammatory mediators, chemokines and growth factors such as 
PDGF and TGFβ, which in turns, promote proliferation of smooth muscle cells and ECM 
deposition (Abraham, 2005).  
 Evidence for endothelial cell injury in SSc includes increased circulating levels of 
factor VIII/von Willebrand factor (endothelium’s product produced in response to 
coagulation stimuli), increased level of circulating platelet aggregates, and increased levels 
of ET-1 (Clements, 2004). 
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1.3.1.2 Vascular Smooth Muscle Cells   
VSMCs are located in the lining of blood vessels, mainly in level of the media, and 
play a key role in the development and regulation of vascular system. They provide first 
vasomotor and arterial tone necessary for maintenance of cardiovascular homeostasis. In 
addition, through their contraction or relaxation, they regulate blood flow and help maintain 
a constant blood pressure.  
However, during a vascular injury, some VSMCs recruit at the injury to participate 
in the remodeling, repair and vascular growth. To accomplish these functions, the VSMCs 
have the ability to modulate their phenotype transiently and reversibly, a phenomenon 
known as phenotypic modulation (Chamley-Campbell, 1979). These cells develop from a 
mature differentiated phenotype called "contractile" phenotype to an immature, 
dedifferentiated one called "synthetic" (Chamley-Campbell, 1981).  
In the media, the majority of normal adult blood vessels VSMCs are generally 
found in the contractile phenotype and are responsible for ensuring vascular tone through 
their elastic properties. These cells, in the contractile phenotype, are found in a quiescent 
state. Their synthetic activity is strongly reduced and the protein repertoire expression is  
almost exclusively limited to the proteins responsible for contraction. In contrast, VSMCs 
have a synthetic cellular machinery much more sophisticated, allowing them to proliferate, 
migrate and synthesize significantly more constituents of the ECM (Thyberg, 1990).  
In vascular damage, VSMCs undergo contractile transient phenotypic modulation. 
First, they migrate, from the media toward the intima. Then, they proliferate and secrete 
glycoproteins, proteoglycans, cytokines and growth factors to participate actively in the 
process of wound repair. Once the injury is repaired, environmental factors within the same 
blood vessel return to their normal composition and physiological function allowing 
VSMCs to regain their phenotype and their properties contractile (Owens, 2004). However, 
under certain conditions, synthetic VSMCs persist the site of injury which, in the long term, 
can contribute to the development and/or progression of vascular disease (Owens, 2004). 
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VSMCs are capable, through their abilities of dedifferentiation and proliferation, to 
promote the development of a number of vascular diseases in SSc (Figure 2, page 12, steps 
5, 6 &7). Evidence suggests that activation of VSMCs leads to migration of these cells into 
the intimal layer of the vessel, where they differentiate into a myofibroblast (Kirk, 1995). 
This transformation of the smooth muscle cell may mediate the progressive fibrosis or 
proliferation of the intima that is typical of SSc vascular disease. The exact mediator of the 
smooth muscle cell activation is unknown, but speculation includes the release of mediators 
from the activated endothelium (e.g., ET-1) and platelets (e.g., platelet derived growth 
factor (PDGF), a very well known phenotypic modulator of VSMCs) (Schachna, 2002). 
In addition, VSMCs in SSc are responsible for abnormal vasoconstrictive response, 
best exemplified by Raynaud’s phenomenon. Some studies suggest that VSMCs in SSc is 
hyper-responsive to α-adrenergic stimuli, thus leading to abnormal cold-induced 
vasoconstrictive responses (Kahaleh, 2008). 
1.3.1.3 Pericytes 
Pericytes are mesenchymal cells that normally reside in the walls of microvessels in 
intimate contact with the underlying endothelium. They play a role in maintaining vascular 
homeostasis. In SSc, Pericytes in the lesion overexpress several cytokine receptors, 
including PDGFR (Rajkumar, 1999). These cells proliferate and contribute to increased 
wall thickness, since activated pericytes can transdifferentiate into collagen-producing 
fibroblasts and myofibroblasts (Helmbold, 2004). 
1.3.2 Connective tissue 
1.3.2.1 Extracellular Matrix (ECM) 
The ECM is a highly organised and dynamic arrangement of macromolecules that 
provides structural support for tissues and cells, and serves as a repository of information. 
The ECM consists of a cellular compartment of resident and infiltrating cells, and of a 
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connective tissue compartment composed of collagens, proteoglycans, elastins, fibrillins 
and adhesion molecules. The ECM also serves as the major reservoir for secreted growth 
factors such as TGFβ, and matricellular proteins such as connective tissue growth factor 
(CTGF), which, together with the connective tissue compartment, provide the cues that 
control differentiation, proliferation, function and survival of resident cells (Varga, 2008).  
Fibrosis is characterized pathologically by replacement of normal tissue architecture 
with collagen-rich ECM, thus results in functional impairment of affected organ. It is the 
result of alteration in the dynamic balance between the accumulation and degradation of the 
ECM in tissue. Excessive connective tissue accumulation mainly collagen types I, III and 
VI, is due to overproduction by fibroblasts and related mesenchymal cells activated by 
soluble factors such as growth factors (TGFβ, PDGF); in an autocrine and/or paracrine 
manner, or by cell-cell or cell-ECM interactions. Impaired ECM degradation and expansion 
of the pool of mesenchymal cells in lesional tissues further contribute to ECM 
accumulation. Evidence suggests that both of these pathways are implicated in SSc, and 
resident fibroblasts are the pivotal effectors cells in the process (Clements, 2004; Varga, 
2008). 
1.3.2.2 Fibroblasts and myofibroblasts 
Fibroblasts are the most common cells of connective tissue and are responsible of 
the ECM and collagen synthesis. Thus, they play critical role in maintaining the structural 
integrity of connective tissues and in wound healing. Under the influence of appropriate 
extracellular signals, fibroblasts are induced to synthesize collagens and other ECM 
macromolecules, to adhere to and contract connective tissue, to secrete growth factors 
cytokines and chemokines, to express surface receptors for these ligands, and to undergo 
transdifferentiation into myofibroblasts. Together, these properties (biosynthetic, 
proinflammatory, contractile, and adhesive) enable fibroblasts to mediate effective wound 
healing.  
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In contrast to physiologic conditions, where the fibroblast repair program is 
controlled tightly and self-limited, pathological fibrosis is characterized by sustained and 
amplified fibroblast activation. This results in exaggerated ECM accumulation and 
remodeling. Inappropriate fibroblast activation is the fundamental pathogenetic alteration 
underlying fibrosis in SSc (Varga, 2008). 
The mechanism of fibroblast hyperactivation in SSc is presently unknown. 
However, many studies have recently highlighted some soluble factors synthesized by the 
fibroblasts themselves, the EC and mononuclear cells, which are responsible for this 
activation. Among these factors, TGFβ plays such an important role in activation and 
survival of fibroblasts. It induces cell proliferation and decreases the susceptibility of 
fibroblasts to apoptosis (Blobe, 2000; Jelaska, 2000). TGFβ may also induce the 
differentiation of fibroblasts into myofibroblasts, which are present in large quantities in 
SSc lesions (Figure 2, page 12, step 4). These cells usually persist longer and are 
responsible for the overproduction of collagen in injured tissues (Jelaska, 1996; 
Desmouliere, 2005).  
Some intrinsic defects, such as genetic and phenotypic alterations have also been 
observed in fibroblasts from SSc patients. Among these, several alterations in signaling 
pathways those regulate the expression of genes encoding for ECM components., In 
particular, alterations at certain family members of SMADs, which are involved in the 
production of collagen type I, are reported (Dong, 2002; Varga, 2002; Mori, 2003). SSc 
fibroblasts also exhibit other features that could encourage the accumulation of collagen in 
patients with the disease such as decreased production of collagenase (Takeda, 1994), 
increased production of collagenase inhibitors (Kirk, 1995) and increased susceptibility to 
certain growth factors (Denton, 1997). Overall, many of the characteristics of SSc 
fibroblasts resemble those of healthy fibroblasts stimulated by TGFβ (Ihn 2008), suggesting 
that TGFβ is a key mediator of tissue fibrosis in SSc.  
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Myofibroblasts express the cytoskeletal protein alpha smooth muscle actin, and  
synthesize collagens and other ECM components. Their primary physiologic role is 
contraction of early granulation tissue during normal wound healing, where myofibroblasts 
are detected transiently and then disappeared. Removal of myofibroblasts from the lesion 
by means of apoptosis is a crucial step in wound resolution.  
In contrast, in pathological fibrogenesis, myofibroblasts persist in lesional tissue, 
resulting in excessively contracted ECM characteristic of chronic scar. In addition, they are 
a major source of TGFβ during the fibrotic response. The presence of alpha smooth muscle 
actin-positive myofibroblasts is associated strongly with fibrotic disorders and SSc, but is 
absent from normal skin (Varga, 2008). 
1.3.2.3 Collagen 
Collagen belongs to a large family that comprises at least 19 distinct proteins 
encoded by at least 31 separate genes. All collagens consist of three polypeptides 
assembled into a unique triple-helical structure. The fibrillar collagens types, which are 
collagen I, II and III, account for more than 70% of total collagens content of tissues. 
Although type I collagen is ubiquitous throughout the body, the distribution of type II 
collagen is restricted to the cartilaginous tissue and vitreous humor. Type III collagen is 
usually in close association with type I and present in appreciable amounts in the skin, 
aorta, gut and lungs (Clements, 2004). 
Patients with SSc have an increase in collagen types 1 and 3, with type 1 being the 
most abundant. Type 1 collagen is encoded by the col1a1 and col1a2 genes, which are at 
least partly controlled by the transcription factor SP1 (Philips, 1995). Increased SP1 
binding activity has been recorded in sclerodermic fibroblasts and its activity has shown to 
be associated with increased gene expression of type 1 collagen in patients with SSc 
(Hitraya, 1998). Gene expression of type 1 collagen is also affected by TGFβ, which 
indicates a possible synergistic profibrotic interaction between SP1 and the TGFβ pathway 
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via the SMAD3/4 complexes (Zhang, 2000). Reduced amounts of SMAD7, which is an 
inhibitor of collagen gene expression, have also been reported in SSc, which suggests that 
the loss of this inhibitory effect allows TGFβ to stimulate unfettered, excessive 
accumulation of ECM (Charles, 2006). 
1.3.2.4 Profibrotic Cytokines 
As illustrated above, profibrotic cytokines are a major driving force in the activation 
of fibroblasts and fibroblast-like cells, resulting in increased release of ECM protein. They  
are often upregulated throughout the course of the disease. Potent pro-fibrotic cytokines, 
produced by various cells, include interleukin (IL-4 and IL-6), chemokines (monocyte 
chemoattractant protein-1 (MCP-1)), connective tissue growth factor (CTGF), transforming 
growth factor β (TGFβ) and platelet-derived growth factor (PDGF) (Sakkas, 2004) (Figure 
3, page 20). Both IL-4 and IL-6 stimulate ECM synthesis (White, 1996; Bruns, 1997). IL-4 
also stimulates fibroblast proliferation and promote T helper (Th2) type immune response 
(Haustein, 1998). This response suppresses IFN, which is an inhibitor of collagen 
synthesis. MCP-1, produced by endothelial cells and other cells, also has profibrotic actions 
via activating collagen and TGFβ1 gene expression in fibroblasts (Gharaee-Kermani, 
1996). CTGF produced by fibroblasts, acts with TGFβ to stimulate collagen synthesis 
(Igarashi, 1995). However, the best-characterized profibrotic cytokines in SSc are TGFβ 
and PDGF. (Table I, page 26, summarizes their role in SSc). Hereafter, we will discuss in 
details these two cytokines and their role is SSc. 
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Figure 3: Activation of Fibroblasts in SSc. Adapted from (Gabrielli, 2009). 
Profibrotic cytokins such as interleukins, chemokines, PDGF and TGF trigger signaling 
cascades in fibroblasts. For example, the phosphorylation of SMAD2 triggers a signaling 
cascade from SMAD3 to SMAD1, which interacts with SMAD4 and regulates gene 
transcription in the nucleus. Activation of TGF and TGFR also results in the activation 
of pathways not involving SMAD proteins, modulating transcription factors. These 
pathways intersect with pathways induced by activation of PDGFR, leading to a complex 
intracellular signaling network. Production of ECM, cytokines and cytokine receptors is 
thereby stimulated; these participate in regulatory loops to sustained fibroblast activation. 
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1.3.2.4.1 Transforming Growth Factor-beta  
 TGFβ is considered the master regulator of physiologic fibrogenesis (wound 
healing) and pathological fibrogenesis. In addition, it has essential roles in normal tissue 
repair, angiogenesis, immune regulation, cell proliferation and cell differentiation. It is 
secreted by platelets, monocytes/macrophages, T cells and fibroblasts. Furthermore, it binds 
to most cell types since they express its specific cell surface receptors (Gu, 2008).  
There are three TGFβ isoforms: TGFβ1, TGFβ2 and TGFβ3. They are structurally 
almost identical but exert different biological functions (Gu, 2008). Each isoform is 
encoded by a distinct gene and synthesized as part of large precursor molecule containing a 
propeptide region. The TGFβ isoform is cleaved from the propeptide before the precursor is 
secreted by the cell, but remains attached to the propeptide by noncovalent bonds. After it 
has been secreted, most TGFβ is stored in the ECM as a large latent complex composed of 
TGFβ, its propeptide, and a protein called latent TGFβ-binding protein (Sinha, 1998); 
(Blobe, 2000). Activation of latent TGFβ to its biologically active form that is capable of 
inducing cellular responses can be mediated by integrins, thrombospondins or matrix 
metalloproteinases (MMPs) (Gu, 2008; Varga, 2008).  
Cell surface receptors for TGFβ family ligands are distinguished from those of other 
growth factors and cytokines by their specificity for phosphorylation of serine or threonine, 
rather than tyrosine residues. Receptor complexes are heterotetrameric, consisting of two 
‘type II’ receptors that bind ligand, and two signal transducing ‘type I’ receptors which, in 
most instances, cannot bind ligand directly and thus are considered to act downstream of 
the type II receptor. TGFβ may also be presented to the type II receptor by the accessory 
proteins betaglycan and endoglin (Leask, 2004).  
Upon ligand binding, an assembly of a heteromeric complex is initiated, and 
stabilized by interactions between the cytoplasmic domains of the type II and type I 
receptors (Roberts, 1999). Thus, once activated, TGFβ binds to the heteromeric receptor 
complex consisting of one TGFβ type I and one TGFβ type II receptor, and triggers an 
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intracellular signal transduction cascade that leads to the induction of target genes 
(Massague, 2006).  
TGFβ signal transduction pathway involves phosphorylation of TGFβRI, which is a 
transmembrane serine-threonine kinase that in turn phosphorylates SMAD2 and SMAD3. 
The latter transduce the signals to the nucleus where they activate downstream gene 
transcription. Ligand-induced signal transduction through the SMAD proteins is tightly 
controlled by the endogenous inhibitors SMAD7 (Varga, 1995; Pannu, 2004). Although the 
SMAD pathway is considered to be the central conduit for signals from the TGFβ 
receptors, emerging evidence highlights the importance of non-SMAD pathways 
(Moustakas, 2005). In fact, recent studies indicate novel roles for some non-SMAD 
pathways, such as the tyrosine kinase c-ABL (Daniels, 2004) and early growth response 1 
(Chen, 2006), in mediating the stimulation of profibrotic responses induced by TGFβ in 
fibroblasts. These novel non-SMAD pathways interact with each other and with SMAD 
proteins in complex, cell lineage–specific signaling networks (Varga, 2007; Gu, 2008). 
In SSc, SMAD-dependent or SMAD-independent signaling downstream of TGFβ 
has been extensively characterized in sclerodermic cells (Figure 3, page 20). Evidences for 
the involvement of SMAD dependent pathway are reduced fibrosis in an animal model of 
SSc via SMAD3 disruption (Lakos, 2004), and impaired inhibitory function of SMAD7 in 
SSc fibroblasts (Asano, 2004). Overall, dysregulated expression or function of activating 
and inhibitory SMAD proteins and their cofactors has been documented in SSc fibroblasts. 
It may also contribute to the initiation or propagation of the abnormal fibrogenic response 
(Varga, 1995; Pannu, 2004). However, evidence for the involvement of SMAD-
independent pathway is the elimination of collagen I and III expression in scleroderma cells 
via inhibiting protein kinase C delta, geranyl transferase1 or stress-activated protein kinase 
p38 (Rosenbloom, 2000; Hayashida, 2007). 
Evidences for the involvement of TGFβ in SSc are the DNA microarray analysis, 
which indicates that a group of TGFβ–dependent genes are overexpressed in biopsy 
  
 
23
specimens from skin lesions in patients. Furthermore, in a mouse model recapitulating the 
clinical and histological features of SSc, enhanced TGFβ signaling in fibroblasts causes 
skin fibrosis. In addition, enhanced TGFβ expression has been extensively detected in 
sclerodermic lesions. Noteworthy, beside the TGFβ role in SSc as the strongest 
myofibroblast inducer, it also modulates the expression of various cytokine receptors, 
including receptors for TGFβ and PDGF (Gabrielli, 2009).  
More specifically, most studies available in literature about the TGFβ role in SSc 
and all evidences mentioned above are related to TGFβ1. In fact, it is undisputed that 
TGFβ1 is a potent profibrotic cytokine, since it stimulates fibroblasts chemotaxis, 
proliferation, expression of α-SMA, and synthesis of collagen as well as other ECM 
proteins. Furthermore, it inhibits ECM degradation by decreasing the synthesis of MMP 
and increasing the synthesis of tissue inhibitor of MMP (Massague, 1990; Nabel, 1993; Gu, 
2008). However, the specific function of the other two TGFβ isoforms in the pathogenesis 
of SSc remains unclear. Although much effort has been made to elucidate their pathologic 
role in SSc, their specific functions remain elusive since results from various studies are 
contradictory (Prelog, 2005; Sgonc, 2008). 
1.3.2.4.2 Platelet Derived Growth Factor (PDGF) 
The PDGF family is composed of four different polypeptide chains, the traditional 
PDGF-A and PDGF-B, and more recently discovered PDGF-C and PDGF-D. The 
biologically active PDGF protein forms disulphide-bonded dimmers including the four 
homodimers PDGF-AA, PDGF-BB, PDGF-CC and PDGF-DD, and one heterodimer 
PDGF-AB. PDGF-A and PDGF-B are processed intracellularly and secreted in their active 
form, while PDGF-C and PDGF-D are secreted as latent factors requiring proteolytic 
activation (Betsholtz, 2003). 
PDGFs exert their biological activities by activating two structurally related tyrosine 
kinase receptors, PDGFRα and PDGFRβ. Ligand-induced receptor homo or 
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heterodimerization leads to autophosphorylation of specific tyrosine residues within the 
cytoplasmic domain. Dimers of PDGF-A (PDGF-AA) activates  PDGFRα homodimers, 
exclusively, while dimers of PDGF-B (PDGF-BB) is capable of  activating PDGFRα, 
PDGFRβ homodimers and PDGFRαβ heterodimer (Betsholtz, 2003). Each of PDGFR is 
characterized by an extracellular binding part and a large intracellular part with a tyrosine 
kinase domain (Malarkey, 1995). The extracellular part is composed of five 
immunoglobulin-like domains (Ig-like), however the ligand-binding function resides in the 
first three domains of the receptors. e.g., Ig-like domain 3 of the PDGFα receptor contains 
epitopes of particular importance for PDGF-AA binding, while the PDGF-BB binding 
epitopes reside in Ig-like domains 1 and 2 (Miyazawa, 1998; Wiesmann, 2000).  
For PDGF receptors, the key event following growth factor stimulation is 
autophosphorylation within the intracellular domain accompanied by dimerization of the 
receptor. Autophosphorylation of the PDGF receptor occurs within a number of regions 
including the kinase insert domain. This phosphorylation promotes interaction of the 
receptor with a number of target proteins or enzymes and induces certain conformational 
change. Thus, leads to induction of several signaling pathways including 
phosphstidylinositol 3 kinase (PI3), Ras-MAPK, Src family kinases and phospholipase Cγ 
(PLCγ) (Malarkey, 1995). Such induction results in cellular proliferation, chemotaxis and 
actin reorganization (Betsholtz, 2003). Noteworthy, PDGFRα and β are structurally similar 
and activate overlapping signal transduction pathways resulting in overlapping biological 
properties in vitro (Trojanowska, 2008).  
In SSc pathogenesis, PDGF plays an important role. It is almost undetectable in 
healthy skin or lung, whereas immunohistochemical studies have revealed increased 
presence of PDGF and PDGF receptors in SSc skin biopsies. In addition, expression of 
PDGF-B was detected in endothelial cell lining of small capillaries and in the infiltrating 
cells (Gay, 1989; Klareskog, 1990). PDGF-A was also prominently expressed in small 
capillaries, around the hair follicles and in selective stromal cells (Yamakage, 1992). 
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Likewise, elevated levels of PDGF-A and PDGF-B were found in bronchoalveolar lavage 
(BAL) fluid obtained from SSc patients (Ludwicka, 1995).  
An interesting observation was made regarding TGFβ regulation of PDGFR  in 
sclerodemic fibroblasts. Indeed, unlike normal fibroblasts, which are unaffected by TGFβ 
treatment or show decreased PDGFR  expression in response to TGFβ, SSc fibroblasts 
respond to TGFβ with up-regulation of PDGFR  (Yamakage, 1992). As a result, TGFβ 
treatment renders SSc fibroblasts more responsive to the subsequent mitogenic stimulation 
with PDGF. This unique characteristic is present in both skin fibroblasts and fibroblasts 
obtained from SSc BAL fluid (Ludwicka, 1995). Relevant to this finding, another study 
have shown that sclerodermic fibroblasts express elevated levels of endogenous IL-1α, 
which in turn stimulates production of PDGF-A (Kawaguchi, 1999). These findings imply 
the existence of an autocrine PDGF-A/PDGFR  loop operating in SSc fibroblasts. 
In addition, beneficial effects of selective inhibitors of PDGF signaling on dermal 
fibrosis had been reported (Akhmetshina, 2008). The functional significance of the 
activation of PDGF signaling in SSc fibroblasts has not been fully evaluated, but it may 
contribute to the enhanced proliferation and migratory and contractile potential of cultured 
SSc fibroblasts. Noteworthy, recent study has also suggested that sera from patients with 
SSc contain pathological autoAbs directed against PDGF receptors (Figure 3, page 20) 
(Baroni, 2006) (this study will be discussed later in details, page 32). These autoAbs were 
capable of stimulating reactive oxygen species and subsequent activation of extracellular 
regulated kinase 1/2 (ERK1/2). This intriguing study, if confirmed, may provide additional 
support for the persistent activation of PDGF signaling and its contribution to SSc fibrosis. 
This new concept, however, awaits additional independent confirmation. 
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Table I: Pro-fibrotic cytokines involved in the pathogenesis of SSc.  
 TGFβ PDGF 
Main cell  
source 
Macrophages, fibroblasts,  
T cells, B cells, platelets, 
EC 
Platelets, macrophages, 
EC, fibroblasts 
Pathogenic 
relevance 
- Induces proliferation of fibroblasts 
and production of CTGF and ET-1;  
- Stimulates synthesis of collagens, 
fibronectin, proteoglycans; 
- Inhibits ECM degradation by 
reduced synthesis of MMP and 
induction of TIMP-1; 
- Serves as mitogen and 
chemoattractant for 
fibroblasts and VSMCs; 
- Induces synthesis of 
collagen, fibronectin, 
proteoglycans;  
- Stimulates secretion of 
TGFβ1, MCP-1 and IL-6; 
Effect in 
scleroderma 
- Stimulates expression of TGFβ and 
PDGF receptors; 
- Increased levels of TGFβ in skin in 
some studies; 
- Elevated expression and 
phosphorylation levels of SMAD2 or 
SMAD3 effectors of TGFβ signaling 
pathway; 
- Elevated levels of TGFβRI in vivo; 
- Elevated expression of 
PDGF and PDGFR in 
skin; 
- Increased levels in BAL 
biologic fluids; 
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1.3.3 Immune System 
The innate and adaptive immune systems both have a role in the pathogenesis of 
SSc (Abraham, 2005). The activation of the immune system is another early and 
predominating event in SSc. Monocytes are among the first cells to migrate into tissues, but 
they seem to play an important role throughout the disease, since they are found 
predominantly in skin biopsies taken at both the early and later phases (Ishikawa, 1992; 
Kraling, 1995). Once activated and migrated to the damaged tissues, 
monocytes/macrophages secrete several soluble factors that can participate not only in (as 
mentioned earlier): 
1. EC activation, increasing synthesis and expression of integrins, thereby accentuating 
the fixing circulating leukocytes on vascular endothelium;  
2. The fibrotic process, influencing growth, differentiation and chemotaxis of 
fibroblasts;  
3. The activation of VSMCs; 
But, also in: 
4.  Activation of other immune cells, such as T and B cells , perpetuating the 
inflammatory cycle (Jimenez, 2004) (Figure 2, page 12, step 2).  
1.3.3.1 T cells 
T cells in skin lesions of SSc patients are predominantly CD4+. They display 
markers of activation, exhibit oligoclonal expansion and predominantly Th2 cells. Th2 
predominant profile is defined by increased levels of anti-inflammatory and profibrotic 
cytokines such as IL-4 and TGFβ, and reduced production of proinflammatory cytokines 
such as IFNγ (Clements, 2004; Abraham, 2005). These characteristics parallel the increased 
serum levels of cytokines derived from Th2 cells in SSc (Gabrielli, 2009). Thus, T cells 
appear to play a role in fibrosis through activation of monocytes and direct release of 
profibrotic cytokines (Clements, 2004). 
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1.3.3.2 B cells 
B cells and plasma cells are occasionally seen among cells infiltrating the skin and 
lung of SSc patients (Lafyatis, 2007; Gu, 2008). An activated B cell signature has been 
demonstrated by microarray analysis in SSc skin (Varga, 2007). Naive B cells and memory 
B cells from SSc patients are both activated and they express increasable levels of CD19, 
which is a cell surface signaling receptor that regulates B cell responses. Transgenic mice 
overexpressing CD19 spontaneously develop high titers of anti-topo I specific Abs 
associated with SSc (Varga, 2007). In addition, depletion of B cells resulted in amelioration 
of skin fibrosis in the TSK1/+ mouse (Hasegawa, 2006). This suggests that altered B cells 
function in SSc might account not only for autoAbs production but also for fibrosis, since 
activated B cells secrete IL-6, which directly stimulates fibroblast (Gu, 2008; Gabrielli, 
2009). 
1.3.3.2.1 Autoantibodies (AutoAbs)  
Each systemic autoimmune disease is characterized by the elaboration of a distinct 
group of autoAbs that target a limited number of ubiquitously expressed antigens (Harris, 
2003). These autoAbs may arise as secondary events either to molecular mimicry or 
consequent to repeated cell damage and release of nuclear antigens (Clements, 2004). 
Virtually, all patients with SSc have detectable serum autoAbs that are either associated 
with the disease phenotype such as antinuclear antibodies (ANA) or with the disease 
pathogenesis like anti-endothelial cell antibodies, anti-matrix metalloproteinase antibodies, 
antifibrillin-1 antibodies and antifibroblast antibodies (Chung, 2004). (The latter 
pathological roles in SSc are illustrated in Table II, page 29).  
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Table II: Autoantibodies with direct pathogenicity in SSc. Adapted from (Chung, 2004). 
Autoantibodies Role of pathogenesis Clinical associations 
Anti-endothelial 
cells 
Incite vascular injury by 
inducing endothelial cell 
apoptosis 
Ischemic digital infracts;  
PAH 
Antifibroblasts Induce fibroblast production 
ICAM-I and IL-6 leading to 
vascular damage and ECM 
production 
Limited SSc 
Anti-
metalloproteinase 
Inhibit MMP-1 collagenase 
activity 
Diffuse SSc 
Antifibrillin-1 Induce instability in 
microfibrils resulting in ECM 
accumulation 
Choctaws American Indian 
and Japanese ethnic 
background 
 
More than 90% of SSc patients have ANA (e.g. ACA, anti-topo I and antinucleolar 
Abs). The major autoAbs in SSc are directed against CENP-A through F, DNA-topo-I and 
less frequently against antinucleolar antigens. SSc-specific autoAbs are associated with the 
major subtypes of the disease and with specific disease manifestation. ACA are found in 20 
to 30 % of SSc patients and are associated with lSSc, significantly reduced frequency of 
pulmonary fibrosis and lower mortality. However, anti-topo I Abs are detected in 9 to 20% 
of SSc patients and are associated with dSSc, pulmonary fibrosis and increased mortality. 
In Addition, heterogeneous group of mutually exclusive autoAbs, which are called 
antinucleolar Abs, are seen in 15 to 40% of SSc patients. Of these, anti-RNA-polymerase I 
and III Abs that are highly specific for SSc and they are associated with diffuse cutaneous 
involvement, SSc-related renal crisis and greater mortality (Gu, 2008). (Table III, page 30, 
is a list of the known ANA in SSc). 
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Table III: Autoantibodies and their clinical associations in patients with SSc. Adapted 
from (Chung, 2004). 
Autoantibodies Cutaneous involvement Clinical associations 
Anti-topo I Diffuse  PF, peripheral vascular disease, cardiac 
involvement, and malignancies 
Anticentromere 
(ACA) 
Limited CREST syndrome, ischemic digital loss, 
isolated pulmonary hypertension and renal 
disease 
Antihistone Limited> 
Diffuse 
Severe PF, cardiac and renal disease, poor 
prognosis 
Antipolymyositis Diffuse or 
Limited 
Severe Raynaud’s phenomenon, arthritis, 
pulmonary disease, calcinosis, myositis and 
benign course 
Anti-Th/To Limited Buffy fingers, small bowl movements, 
hypothyrodism, PF and renal crisis 
Anti-U3-snoRNP 
(fibrillarin, 
Mpp10, h-U355k) 
Diffuse or 
Limited 
African-American ethnicity, cardiac and renal 
disease, and gastrointestinal involvement 
Anti-UI-SnRNP 
proteins  
Anti-UI-snRNA 
Diffuse or 
Limited 
Severe Raynaud’s phenomenon, MCTD, PF 
and renal crisis 
Anti-RNA 
polymerase 
Diffuse renal crisis 
Anti-B23 Limited> 
Diffuse 
PAH and malignancies 
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1.4 Treatment 
Treatment of SSc is largely empirical and rarely evidence based (Maddison, 2002). 
It has been somewhat haphazard and treatment has often been benefiting from the 
experience gained from treating other connective tissue diseases. The choice of therapy is 
complex and depends on the type of SSc (diffuse versus limited); the stage of illness (early 
versus late); and the specific organ-related problems faced by the individual patient 
(Charles, 2006).  
At present, there are no known treatments to change the overall course of SSc. 
However, survival has improved dramatically in recent years due to the effectiveness of 
treatments directed at specific internal organ features. These include drugs for PAH such as 
epoprostenol, treprostinil and iloprost, which can supply prostacyclin that the pulmonary 
vascular endothelium itself no longer supplies in adequate quantities. Moreover, bosentan, 
which is ET receptor antagonist, is also used because, as mentioned earlier, ET 
(vasoconstrictor mediator) is frequently increased in the serum of patients with SSc-PAH. 
In addition, other drugs are used for other SSc manifestations. Angiotensin-converting 
enzyme inhibitors (ACEI) are the preferred choice in the management of renal crisis, the 
fatal complication of SSc. Moreover, immunosuppressive, such as, cyclophosphamide, d-
penicillamine, methotrexate, and corticosteroid are used for pulmonary inflammation 
(Charles, 2006). Furthermore, antifibrotic therapy e.g. INFα and β, and recombinant human 
relaxin have been tested in controlled trials but did not show any benefits (Panayiotis, 
2001).  
Tyrosine kinases (TK) are promising targets for antifibrotic treatment approaches in 
SSc due to their central role in production and release of ECM. Investigation for tyrosine 
kinase inhibitors (TKIs) is currently available. The TKI imatinib, a dual inhibitor of 
Abelson kinase (c-Abl) and PDGF receptor, is currently investigated in clinical proof-of-
concept trials for the treatment of patients with SSc (Akhmetshina, 2009). In addition, 
further TKIs such as nilotinib (Bcr-Abl tyrosine kinase inhibitor) and dasatinib (SRC-
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family protein-tyrosine kinase inhibitor) with potent antifibrotic effects are emerging from 
preclinical studies. In contrast to TKIs of c-Abl and PDGF receptor, the role of vascular 
endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) 
TKIs in the treatment of SSc remains unclear (Akhmetshina, 2008; Beyer, 2010). 
UVA phototherapy could be implicated in treatment of SSc because of its major 
immunosuppressive effects via the induction of apoptosis of T cells, impairment of cell 
proliferation and the induction of inhibitory cytokines like IL-10. However, results of 
various studies are conflicting and controlled studies are currently in progress 
(Hunzelmann, 2010). 
Clinical research on therapies for SSc is currently very active. The future and 
present trials should focus on the cellular mediators in SSc as potential therapeutic targets 
(Charles, 2006).  
1.5 Rational, Hypothesis and Objectives 
1.5.1 Anti-PDGFR Stimulatory AutoAbs in SSc Link between 
Autoimmunity and Fibrosis 
A common feature of all the Abs found in SSc is their inability to activate selective 
signaling pathways. Their production is probably secondary to cell breakdown induced by 
inflammation. Recently, a novel class of Abs has been discovered in SSc patients. They 
appear to be the first identified link between the activation of immune system and tissue 
fibrosis. The novel link is between B-cell-mediated autoantibody production and 
upregulated PDGFR signaling in SSc that was provided by Baroni et al. study (Baroni, 
2006). This Italian group showed that there are autoAbs from sera of patients of SSc that 
bind and stimulate PDGFR in fibroblasts, which in turn stabilizes RAS and induce ERK1/2. 
Induction of ERK1/2 increases levels of reactive oxygen species (ROS). The long-term 
persistence of ROS and ERK1/2 ultimately results in the stimulation of collagen gene 
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expression (Baroni, 2006). This interesting study provides additional support for the 
persistent activation of PDGFR signaling and its contribution to SSc fibrosis. However, 
other studies contradict the presence of agonistic Abs to PDGFR (Classen, 2009; Loizos, 
2009). Noteworthy, the PDGFR stimulatory autoAbs  found not to be specific for SSc. 
They have also been detected in graft versus host patients (Svegliati, 2007) and in systemic 
lupus erythematosus (SLE) (Kurasawa, 2010). Thus, the presence of stimulatory autoAbs to 
PDGFR in SSc must be verified in larger number of patients affected by SSc and different 
laboratories.   
Vascular complications are another hallmark of SSc. In SSc, the homeostatic 
function of endothelium is disrupted by EC activation and/or injury. Endothelial cell (EC) 
injury is the critical early event in SSc-associated pulmonary vascular disease such as PAH. 
In PAH, EC injury leads to alterations in endothelial function with increased production of 
vasoconstrictor mediators and decreased synthesis of vasodilator ones (Varga, 2002). In 
addition, damage to the endothelium in SSc induces the release of proinflammatory 
mediators, chemokines and growth factors such as PDGF and TGFβ, which in turns, 
promote proliferation of smooth muscle cells and ECM deposition (Abraham, 2005).  
 The investigation of the effects of anti-PDGFR on EC and VSMCs would bring the 
vascular components of SSc into the picture and provide better understanding to the 
interacting systems in this disease. Therefore, if anti-PDGFR autoAbs were present in the 
circulation of SSc patients, they would most certainly encounter VSMCs. The latter are 
known to express the PDGFR and response to PDGF, which is a known phenotypic 
modulator of VSMCs (Rensen, 2007). Thus, we hypothesized that VSMCs will  response to 
autoAbs against the PDGFR leading to the activation of ERK and the induction of genes 
involved in fibrotic responses.  
In order to prove this hypothesis the following specific objectives will be 
investigated in this study (Figure 4, page 35). 
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1.5.2 Objective 1: Involvement of SSc-IgG in activating downstream 
pathway of PDGFR in VSMCs  
There are several signaling cascades induced by PDGFRs. One of these downstream 
pathway is MAPK. The latter has been proposed to play an important role in cell growth 
and differentiation stimulated by PDGF (Malarkey, 1995). It is possible that autoAbs to 
PDGFR could act as mitogen just as the endogenous cytokine and induce ERK1/2. Thus 
ERK phosphorylation will be measured by immunoblot analysis to assess the response of 
VSMCs to autoAbs from SSc patients.  
1.5.3 Objective 2: Involvement of SSc-IgG in affecting fibrotic genes in 
VSMCs 
According to Baroni et al study, upregulated PDGFR signaling by SSc autoAbs 
results in the stimulation of collagen gene expression. Since patients with SSc have an 
increase in collagen types 1 and 3 (Philips, 1995), we will test the effect of SSc-IgG on 
collagen 1 (col1a1) and collagen 3 (col III) genes expression. In addition, we will also 
assess the effect of these autoAbs on tgfb genes since TGFβ1 is a key mediator of tissue 
fibrosis (Ihn, 2008). Indeed, in SSc, the role of TGFβ1 as a fibroblasts’ activator and a 
potent stimulator of collagen production is well defined, but the specific function of the 
other two isoforms in the pathogenesis of SSc remains unclear (Ihn, 2008). Thus, we will 
study the effect of SSc-IgG on the mRNA expression of the three different isoform (tgfb1, 
b2 and b3). The study of the 5 different genes will be accomplished by the RT-qPCR 
method. 
1.5.4 Objective 3: Involvement of PDGFR in the molecular events 
noticed in VSMCs in response to SSc-IgGs 
The third objective is to verify the  involvement of PDGFR in  the molecular events 
noticed in VSMCs in response to SSc-IgGs. In order to achieve this, two assays will be 
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performed. First, we will immunoprecitpitate the PDGFR by SSc-IgG and controls. Second, 
we will use the highly characterized PDGFR tyrosine kinase inhibitor, the tyrphostin 
AG1296. 
 
 
Figure 4: Schematic diagram represents the objectives of the research. Modified from 
(Baroni, 2006).
  
Chapter 2: Material and method 
2.1 Patients’ characterization 
The Canadian scleroderma research group (CSRG) provided us with sera samples of 
controls and SSc patients as well. Nine controls were used in our study. The controls were 
either normal people or patients with osteoarthritis (OA), which is a degenerative disease of 
degradation of the joint with no inflammation or systemic autoimmunity features (Cooke, 
1987). The controls were age and sex matched. The SSc patients’ sera were randomly 
selected from CSRG bank. We studied 19 patients with SSc (2 men and 17 women) with a 
median age of 51 years (range 23 to 75). All patients have disease duration less than 5 years 
with a diffuse type of the disease. These patients had not received any immunosuppressive 
treatment. Of 19 patients, seven had anti-RNA polymerase antibodies and four had anti Scl-
70 antibodies. (Demographic characteristics of patient outlined in Table IV, page 36). 
Table IV: Demographic characteristics of SSc patients involved in this study 
Sex Race Age Characteristics Male Female White Others Median Range 
Systemic Sclerosis (N=19) 2 17 17 2 51 23-75 
Duration of disease < 5 years 
 
2.2 Reagents (antibodies, agonists) 
PDGF-BB and TGFβ1 was purchased from R&D system (Minneapolis). Phospho-
ERK1/2 (Thr202-Tyr204) antibody (#9101) and anti-ERK1/2 (#9102) are from Cell 
Signaling Technology (Beverly, MA). Anti-PDGFRβ (# 06-495) was purchased from Up 
State Millipore, while the (PDGF) α and β receptors inhibitor AG1296 (# 658551) was 
purchased from Calbiochem (Gibbstown, NJ). 
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2.3  IgG purification 
The IgG fractions where purified from sera of controls and SSc patients by affinity 
chromatography using Protein A/G agarose 15ml settled resin (Pierce). Sera samples 
(300µl) were diluted 1:1 with a binding buffer, phosphate buffered saline (PBS), and then 
applied to a gravity-flow column (Pierce) packed with 300µl of protein A/G allowing the 
IgG binding. Then, the protein A/G column is washed from the non-bound serum 
components by several washing steps (4 washes with PBS 5ml and three washes with 1M 
NaCl 200µl). Finally, IgG elution buffer 200µl (Pierce) is used to elute the IgGs and the 
eluted IgG fractions are neutralized using 20µl of Tris- HCL PH 8.5.  
The mature native PDGF isoforms  have a molecular weight of ~30,000 Dalton 
(Heldin, 1999). Thus, a size-exclusion chromatography was added to the purification 
procedure to remove trace amounts of contaminating cytokines. Amicon Ultra-4 device 
(Millipore) 100K is used for this purpose. It concentrates the sample to be collected from 
the filter and allow the flow of any molecule with a molecular weight less than 100,000 
Dalton. 
2.4 Cell Culture  
 Rat aortic VSMCs were obtained from Dr. Darren Richard (Hôtel-Dieu de Québec, 
QC, Canada) and grown in high glucose Dulbecco’s modified eagles medium (DMEM) 
supplemented with 10% fetal bovine serum (FBS). Cultured cells were maintained at 37°C 
in a humidified atmosphere of 95% air and 5% CO2. Quiescent VSMCs were obtained by 
incubation of 80% confluent cell cultures in serum-free high glucose DMEM, Ham's F-12 
(1:1) supplemented with 15mM Hepes (pH 7.4), 0.1% low endotoxin bovine serum 
albumin (Sigma, Saint Louis, MO), and 5µg/ml transferrin (Sigma, Saint Louis, MO) for 48 
hours. 
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For experiments with pharmacological inhibitors, the cells were treated with vehicle 
alone or with the indicated concentrations of the inhibitor for 30 min before addition of 
PDGF-BB or IgG fractions.  
2.5 Immunoblot analysis 
After the different treatments, cells were washed twice with ice-cold phosphate-
buffered saline (PBS), and whole cell extracts were prepared using Triton X-100 lysis 
buffer (50mM Tris-HCl, pH 7.4, 150mM NaCl, 50mM sodium fluoride, 5mM EDTA, 
40mM β-glycerophosphate, 1mM sodium orthovanadate, 10-4M phenylmethylsulfonyl 
fluoride, 10-6M leupeptin, 10-6M pepstatin A, 1% Triton X-100, 10% glycerol) for 30 min 
at 4°C. All cellular extract is subjected to centrifugation at 13,000g for 10 min, and were 
quantified by the BCA method. Equal amounts of lysate proteins (20-50µg) were subjected 
to electrophoresis on 7.5, or 10% acrylamide gels. Proteins were electrophoretically 
transferred onto a nitrocellulose membrane for two hours at 4ºC in a transfer buffer with 
methanol (14.4g/L glycine, 3g/L TRIS and 20% methanol). Then the membrane is blocked 
for an hour in a solution of TBS 0.1% Tween 20 containing 5% milk and then incubated in 
primary antibody with specifications of each. The membrane is then washed 5 times 5 
minutes in TBS 1% Tween 20 then incubated for 2 hours in secondary antibody coupled to 
peroxidase. The membrane was washed again, 5 times 5 minutes in TBS 1% Tween 20 and 
then the presence of proteins of interest is revealed by using ECL+ (enhanced 
chemiluminescence). 
2.6 RT real time-PCR  
Total RNA was isolated using RNeasyMini kit (QIAGEN) according to 
manufacturer’s instructions. Spectrophotometric quantification of RNA samples was 
performed. Accepted ratio of (A260/A280) for pure RNA was 1.9-2.1 in 10mM Tris-Cl PH 
7.5. RNA samples were further analysed on a Bioanalyzer system at Genomic platform, 
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Institute for Research in Immunology and Cancer (IRIC), to verify RNA integrity before 
proceeding to QPCR assay. Total RNA (2µg) was reverse transcribed using the High 
Capacity cDNA Reverse Transcription Kit with random primers (Applied Biosystems) as 
described by the manufacturer. Real-time PCRs were subsequently performed using the 
Fast SYBR Green Master Mix (Applied Biosystems) with the following rat forward and 
reverse primers (Table V, page 39): 
Table V: Sequences of primers used to study genes expressions. 
 
Quanitect primer assay (QIAGEN) was used for col1a1. β-actin endogenous control 
was used for sample standardization. The qPCRs were performed using the following 
schedule: initial step of 3 min at 95˚C, followed by 40 cycles of: 5 sec at 95˚C and 30 sec at 
60˚C. All reactions were run in triplicate and the average values of Cts were used for 
quantification. The relative quantification of target genes was determined using the ΔΔCT 
method. Briefly, the Ct (threshold cycle) values of target genes were normalized to an 
Gene Primers 
FWD 5`AGATGCTGGTGCTGAGAAG3`   
colIII 
REV 5`TGGAAAGAAGTCTGAGGAAGG3` 
FWD 5`CCTGGAAAGGGCTCAACAC3` 
tgf1 
REV 5`CAGTTCTTCTCTGTGGAGCTGA 3` 
FWD 5`AGTGGGCAGCTTTTGCTC3` 
tgf2 
REV 5`GTAGAAAGTGGGCGGGATG3` 
FWD 5`AGTGGCTGTTGCGGAGAG 3` 
tgf3 
REV 5` GCTGAAAGGTATGACATGGACA3` 
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endogenous control gene (β-actin) (ΔCT = Ct target – Ct CTRL) and compared with a 
calibrator: ΔΔCT = ΔCt Sample - ΔCt Calibrator. Relative expression (RQ) was calculated 
with the formula RQ = 2-ΔΔCT. 
2.7 Co-immunoprecipitaion 
500μg of whole cell extracts were incubated for 4 hours at 4°C with 2µg of anti-
PDGFRβ (Up State, Millipore), 200µg of SSC or controls-IgGs. The latter were 
preabsorbed to 50µl protein-A-sepharose beads. The immune complexes were washed four 
times with Triton X-100 lysis buffer and 2X Laemmli’s sample buffer was added. The 
immunoprecipitated protein analysed by immunoblot analysis.  
2.8 Statistical analysis 
Statistical analysis was performed using GraphPad Prism version 5.0 for Mac 
(GraphPad Software, San Diego, CA). Comparison of two groups was carried out using a 
two-tailed unpaired t-test, and comparison of more than two groups was carried out with 
one-way ANOVA and a Bonferroni post-test. Statistical significance was accepted at a P-
value below 0.05. 
 
 
  
Chapter 3: Results 
3.1 SSc-IgG has growth properties on VSMCs 
In general, PDGF-stimulated cell proliferation is mediated via the activation of Ras 
and the downstream MAPK signaling pathway (Bonner, 2004). We hypothesized that SSc-
IgG will act as the endogenous cytokine PDGF and will induce ERK in VSMCs. To prove 
this hypothesis, first a kinetic assay in rat VSMCs is performed to demonstrate that VSMCs 
respond to PDGF and to determine the optimal time for ERK phosphorylation through 
PDGFR in these cells. A specific concentration of PDGF-BB,  which is capable of  
activating PDGFRα, PDGFRαβ and PDGFRβ (Betsholtz, 2003), is used for different time 
course. The maximal phosphorylation of ERK was obtained after 5 minutes of PDGF-BB 
stimulation and reduced with longer exposition time (Figure 5, page 41). Thus, 5 minutes is 
the optimal time used to expose VSMCs to SSc-IgG. 
 
Figure 5: Time course effect of PDGF on ERK activation in VSMCs 
Quiescent VSMCs left untreated or exposed to PDGF-BB 50ng/ml for time indicated. Then 
cells lysates were separated on 10% SDS gel and subjected to immunoblotting analysis 
using indicated antibodies. This result is representative of three independent experiments. 
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Total IgG is purified from patients with SSc and controls to eliminate the 
confounding effect of PDGF or other cytokines present in the sera. Then, cells were 
exposed to different SSc-IgGs as well as IgGs from controls. PDGF-BB is used to control 
efficiency of the experimental procedure. The use of an anti-phospho ERK1/2 (Thr202-
Tyr204) antibody in Western blot analysis revealed that SSc-IgG were able to 
phosphorylate ERK more than controls-IgG (Figure 6, page 42). The phosphor ERK signals 
in response to most (68%, 19/28) SSc-IgG samples was markedly stronger than in controls, 
of which only 27% (3/11) gave an above-basal signal. Of which gives evidence that 
VSMCs respond to SSc-IgG and activate MAPK cascade, a downstream pathway of growth 
factors receptors.  
 
Figure 6: SSc-IgGs phosphorylate ERK more than controls-IgG in VSMCs 
Quiescent cells were left untreated or exposed to PDGF-BB 50ng/ml, 200g of purified 
IgG of controls or SSc patients for 5 minutes. Then ERK phosphorylation was measured by 
immunoblot analysis. Normalization of ERK phosphorylation is accomplished by stripping 
the nitrocellulose membrane and reprobing with an antibody against total ERK. This result 
is representative of five independent experiments. 
 
T-ERK 
P-ERK 
Control 
Basal PDGF Ct2 OA5 SSc27 SSc28 SSc29 
SSc 
  
 
43
3.2 SSc- IgG has a profibrotic role in VSMCs 
It has been reported that upregulated PDGFR signaling by SSc autoAbs results in 
the stimulation of collagen gene expression in fibroblast (Gabrielli, 2006). To test the 
capacity of SSc-IgG to affect collagen expression in VSMCs, we verified first PDGFR 
activation aptitude to induce col1a1 and colIII expression. Thus, time course assay with 
PDGF is performed to validate the optimal time for collagen induction (Figure 7, page 44). 
TGFβ1, a very well known inducer of collagen expression in VSMCs, is used to control 
efficiency of the assay (Massague, 1990; Miyazawa, 1995). As a result, we found that 
PDGF neither induced col1a1 (Figure 7A) nor colIII (Figure 7B) for the time-course 
indicated, even though TGFβ1 was able to induce col1a1 and colIII gene expression by 
almost 4.5 folds at 72 hours (Figure 7 A&B). 
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Figure 7: Time course of PDGF effects on col1a1 and colIII genes expression in 
VSMCs 
Quiescent VSMCs were treated with PDGF-BB (50ng/ml) or TGF1 (10ng/ml) for the time 
indicated. RT-QPCR was used to detect messenger RNA encoding col1a1 (A) and colIII 
(B). Fold changes were calculated relative to the average of triplicate untreated samples by 
the comparative CT formula 2-ΔΔCT. Representative result of two independent experiments 
is shown. 
 
A 
B 
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Previous data obtained in vitro indicated that PDGF mediates procollagen synthesis 
only indirectly through enhancing the expression of tgfb genes in macrophage and in 
fibroblast in vitro (Pierce, 1988; Van Obberghen-Schilling, 1988). Therefore, in accordance 
with a lack of a significant effect of PDGF in inducing collagen genes following 72 hours 
of exposition, our data could correlate with this proposition. Thus, we further investigate 
PDGF effect on tgfb genes by time-course assay to validate the best time to expose cells to 
SSc-IgG.  
It is well documented that the three TGFβ isoforms are structurally almost identical 
but exert different biological function and each isoform is encoded by a distinct gene 
(Blobe, 2000). Thereby, we studied the effect of PDGF on the expression of three different 
isoforms (tgfb1, tgfb2 and tgfb3). Tgfb genes showed variable responses to PDGF (Figure 
8, page 46). The tgfb1 and tgfb3 expression were significantly upregulated ~3 folds. An 
increase in tgfb1 can be detected within 1h following PDGF addition; it reaches a peak by 
2h and carries on to 6h (Figure 8A). Tgfb3 increase can be detected as early as 30 minute to 
reach the maximum induction at 1 to 2h (Figure 8C). In contrast to tgfb1 and tgfb3, tgfb2 
expression is negatively regulated by PDGF. Its downregulation noticed at 2h, reached a 
maximal 0.15 fold reduction at 6h and remained low by 12h (Figure 8B). Thereby, the 
PDGF common influence on tgfb genes expression was observed at 2h. Thus, it is the target 
time chosen to study SSc-IgG effect on these genes.  
Of note, it has been previously reported that TGFβ1 positively regulates its own 
expression in fibroblast cells (Van Obberghen-Schilling, 1988). Noteworthy, our data 
replicate the autoinduction of tgfb1 expression at 2h in VSMCs as well (Figure 8A). Thus, 
it is used as additional positive control in the following RT-qPCR assays. 
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Figure 8: Time course of PDGF effects on tgfb genes expression in VSMCs 
Quiescent VSMCs were treated with PDGF-BB (50ng/ml) or TGF1 (10ng/ml) for the time indicated. RT-QPCR was used to detect 
messenger RNA encoding tgfb1, tgfb2 and tgfb3. Fold changes were calculated relative to the average of triplicate untreated samples by the 
comparative CT formula 2-ΔΔCT. Representative results of one of two experiments are shown. *** p<0.001, ** p<0.01, * p<0.05 
A B C 
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3.2.1 SSc-IgG induces tgfb1and tgfb3 gene expression in VSMCs 
SSc-IgGs effect on tgfb genes expression is investigated in two cohorts of patients. 
In the first one, RT-QPCR analysis showed that tgfb1 mRNA levels are ~2 folds high by 
SSc-IgG but not by control IgG (Figure 9 A1, page 48). The difference between SSc-IgG 
effect and control-IgG on tgfb1 were highly significant (Figure 9 A2). Similarly, in the 
second cohort, tgfb1 expression was upregulated by SSc-IgG (Figure 9 B1). Even though 
some controls rise up tgfb1 level, the induction by SSc-IgG was significantly higher than 
controls with a p value <0.001 (Figure 9 B2). 
Tgfb3 expression revealed a similar pattern as tgfb1 in the first cohort with 2.5-4.8 
folds increase in response to SSc-IgG (Figure 10 A1&A2, page 50). However, its 
expression in the second cohort was less, since results showed that the difference between 
SSc-IgG effect and control-IgG were not significant (Figure 10 B1&B2).  
Although the role of TGFβ3 in the pathogenesis of SSc is difficult to describe, 
various studies suggest its fibrotic role (Shinozaki, 1997; Querfeld, 1999). And, as 
mentioned before, TGFβ1 is a potent fibrogenic cytokine. Thus, our data suggest a role of 
SSc-IgG in inducing profibrotic genes. 
3.2.2 SSc-IgGs reduced tgfb2 expression in VSMCs 
Unexpected finding is that SSc-IgG caused a ~0.32-0.58 fold decrease in tgfb2 
mRNA level in the experiments of two groups presented in (Figure 11 A1&B1, page 52). 
Moreover, the reduction of tgfb2 expression was significantly higher in response to SSc-
IgG than controls in both groups (Figure 11 A2&B2).  
Noteworthy, upon investigating SSc-IgGs effect on the expression of collagen type I 
and III, RT-qPCR analysis showed that SSc-IgGs neither induce mRNA level of col1a1 nor 
colIII  in VSMCs after 2h exposition ( data not shown). 
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Figure 9: Upregulation of tgfb1 expression by SSc antibodies in VSMCs 
(A1, B1) Quiescent VSMCs were left untreated or exposed to buffer (used in IgG 
purification), PDGF-BB (50ng/ml), TGF1 (10ng/ml), control-IgGs (C, OA) or SSC-IgGs 
for two hours. RT-QPCR was used to detect messenger RNA encoding tgfb1. Fold changes 
were calculated relative to the average of triplicate untreated samples by the comparative 
CT formula 2-ΔΔCT.  
(A2, B2) unpaired t-test comparing two groups.  
*** p<0.001, ** p<0.01, * p<0.05 
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Figure 10: Upregulation of tgfb3 expression by SSc antibodies in VSMCs 
(A1, B1) Quiescent VSMCs were left untreated or exposed to buffer (used in IgG 
purification), PDGF-BB (50ng/ml), TGF1 (10ng/ml), control-IgGs (C, OA) or SSC-IgGs 
for two hours. RT-QPCR was used to detect messenger RNA encoding tgfb3. Fold changes 
were calculated relative to the average of triplicate untreated samples by the comparative 
CT formula 2-ΔΔCT. 
(A2, B2) unpaired t-test comparing two groups. 
*** p<0.0001, *** p<0.001, * p<0.05 
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Figure 11: Downregulation of tgfb2 expression by SSc antibodies in VSMCs  
(A1, B1) Quiescent VSMCs were left untreated or exposed to buffer (used in IgG 
purification), PDGF-BB (50ng/ml), TGF1 (10ng/ml), control-IgGs (C, OA) or SSC-IgGs 
for two hours. RT-QPCR was used to detect messenger RNA encoding tgfb2. Fold changes 
were calculated relative to the average of triplicate untreated samples by the comparative 
CT formula 2-ΔΔCT.  
(A2, B2) unpaired t-test comparing two groups.  
*** p<0.001, ** p<0.01 
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3.3 Involvement of PDGF receptor in the molecular events 
noticed in VSMCs in response to SSc-IgGs 
To prove that ERK-inducing activity was mediated by the activation of PDGFR, we 
performed two additional experiments. First, we inquired whether the SSc-IgG could 
immunoprecipitate PDGF receptor from a whole cellular extract of VSMCs (Figure 12A, 
page 55). Both control and SSc patients immunoprecipitated the PDGFR; however the SSc 
significantly immunoprecipitate more PDGFR than control (Figure 12 B2). Only faint 
PDGFR bands were detected in control treatments, while 75% of the SSc-IgG samples 
tested immunoprecipitated the PDGFR much more strongly. Second, to further substantiate 
the role of PDGFR, we used the highly characterized PDGFR tyrosine kinase inhibitor, the 
tyrphostin AG1296. Dose response assay with AG1296 was performed on VSMCs (Figure 
13A, page 57). 5µM is the optimal concentration for AG1296 to inhibit ERK 
phosphorylation triggered by PDGF since higher concentration may cause unselective 
inhibition. Surprisingly, the use of AG1296 did not block these SSc-IgG-induced ERK 
phosphorylations, despite effectively blocking these signals in PDGF-stimulated cells 
(Figure 13B). Together, the results of the last two experiments suggest that either these 
properties of SSc-IgGs are not mediated through PDGFR or their effects interfere with 
PDGFR independently of its kinase activity. 
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Figure 12: SSc-IgG pulled down PDGFR more than controls 
(A) 500µg of VSMC whole cell extract is subjected to immunoprecipitation using 200µg of 
Purified IgG from control and SSC patients. The immunoprecipitated protein is then 
analysed by immunoblot analysis using anti-PDGFRβ antibody. “Total lysate” indicates 
immunoblots of total protein. Representative results of one of two experiments are shown.  
(B1) is the results of densitometric analysis of two independent experiments.  
(B2) is the difference between SSc and controls in these experiments.  
* p<0.05 
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Figure 13: ERK phosphorylation in response to SSc-IgG was independent of the 
tyrosine kinase phosphorylation of the PDGFR  
(A) Cells were pre-exposed to the concentrations indicated of AG1296 30 min before 
stimulation with PDGF. The ERK phosphorylation was measured by immunoblot analysis. 
(B) Cells were pre-exposed to 5M AG 1296 or DMSO 30 min before stimulation with 
PDGF 50ng/ml or purified IgG from control and SSc patients. Cell extracts were prepared 
and subjected to immunoblotting analysis using indicated antibodies. One of two 
independent experiments with similar results is shown. 
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Chapter 4: Discussion 
Our results, in term of ERK activation, indicate that autoAbs from SSc patients were 
able to phosphorylate ERK in VSMCs more than controls (Figure 6, page 42). However, 
the SSc-IgG effect was not noticed in all SSc patients. Although the Italian group (Baroni et 
al) claimed that the stimulatory Abs to the PDGFR were found in all patients with SSc, 
serological studies in CSRG laboratories showed that anti-PDGFR autoAbs exist in almost 
5% of patients tested not all (unpublished observation). In addition, our findings correlate 
with the fact that SSc is very heterogeneous and that the frequency of SSc autoAbs varies 
depending on the ethnic and racial groups (Okano, 1996; Harvey, 1999). I.e. in Quebec, 
frequency of anti-topo I in French Canadian with diffuse SSc is the lowest reported ~13.8% 
(Scussel-Lonzetti, 2002). Nevertheless, in Italy, the frequency of anti-topo I was over 50% 
(Giordano, 1986; Ferri, 1991). Thus, whether the discovered autoAbs to VSMCs in this 
study are the anti-PDGFR autoAbs or not, it is predicted not to find these autoAbs in all 
SSc patients and they are not a specific hallmark to SSc. 
We further investigate the effect of SSc-IgG on genes involved in fibrogenic 
response (Ihn, 2008). Even though, the TGFβ superfamily has a shared structure and 
similar signaling pathways, they have overlapped biological effects (Ihn, 2008). It is well 
known that the most potent profibrotic stimulus to fibroblasts is TGFβ1. In SSc, it is well 
documented that it activates fibroblasts and stimulates collagen production, but the specific 
function of the other two isoforms remains unclear because results from various studies are 
contradictory (Cotton, 1998; Denton, 2001). Among these, immunohistochemical studies 
concluded that TGFβ 2 and 3 play important roles in the induction of collagen synthesis in 
SSc, since collagen mRNA was found to be induced in the same areas where their 
expression was noted (Kulozik, 1990; Querfeld, 1999). Whereas, other studies showed no 
significant difference in levels of these isoforms’ expression in patients with SSc and 
control (Coker, 2001; Whitfield, 2003). Lately, microarray study on gene expression 
patterns in SSc skin showed reduced TGFβ2 expression in SSc skin biopsy samples as 
compared with healthy control skin (Whitfield, 2003). Moreover, studies in the BAL fluid 
of patients with SSc found that concentrations of TGFβ2 levels are reduced, as compared 
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with controls (Meloni, 2004). Interestingly, a study on UCD-200 line of chickens, the only 
spontaneous animal model showing the 3 main hallmarks of SSc, i.e., vascular alterations, 
mononuclear cell infiltration and fibrosis, demonstrated that TGFβ2 significantly inhibited 
the expression of procollagen leading to the same levels as seen in controls (Prelog, 2005). 
In addition, in the same study, the constitutive overproduction of the procollagen mRNA 
and the diminished synthesis of TGFβ2 in untreated UCD-200 also suggest that TGFβ2 is 
an antifibrotic cytokine. These results shed light on the contradictory observations 
regarding the role of TGFβ2 in human SSc and support its role as antifibrotic cytokine. 
Although TGFβ3 expression and its role in SSc are still less defined, various studies 
suggest its fibrotic role (Shinozaki, 1997; Querfeld, 1999; Coker, 2001; Sgonc, 2008). 
In our study, we analyzed the influence of SSc-IgG on the three TGFβ isoforms’ 
expression. We found autoAbs to VSMCs that are able to induce mRNA level of the tgfb1 
(Figure 9, page 48) and tgfb3 (Figure 10, page 50), whereas tgfb2 is significantly reduced 
(Figure 11, page 52). Tgfb1 was upregulated by 2-fold (p<0.001) in VSMC treated with 
SSc-IgG, as compared to those treated with control IgG. Tgfb2 mRNA was downregulated 
by 20 to 40% (p<0.001) in SSc-IgG treated VSMCs. These data give insight, for the first 
time, to the existence of pathological autoAbs to VSMCs in SSc patients that are able to 
create imbalance between pro and antifibrotic cytokines in favour of fibrosis. We reported 
upregulation of tgfb3 expression in SSc-IgG treated VSMCs more than control-IgG treated 
ones; however, the difference between these two groups was not significant. Further 
experiment is suggested to conclusively rule out the SSc-IgG effect on tgfb3 expression. 
Interestingly, some control-IgG induced tgfb1 and reduced tgfb2 expressions as well 
(Figure 9, page 48; Figure 11, page 52). As mentioned earlier, also some controls-IgG 
induced ERK phosphorylation. Similar observations have been reported in studies on 
stimulatory PDGFR autoAbs (Balada, 2008; Classen, 2009; Loizos, 2009). The existence of 
such autoAbs in normal people that possess lower effect on the molecular events noticed 
with SSc-IgG raised two possibilities.  
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First, Abs in controls may not recognise the same specific epitope that trigger the 
receptor in SSc or have a lower affinity to that epitope. In other words, it is not only the 
presence or absence of these autoAbs but also the location of the epitope recognised by 
them in their specific receptor. Thus, possibly these autoAbs exist in normal people 
however they have lower affinity to their receptor to trigger a pathological response. Such 
phenomenon had been discussed in Graves’ disease since thyroid-stimulating hormone 
receptor (TSHR) has been detected not only in Graves’ disease, but also in 55% of 
euthyroid control subjects (Atger, 1999). In the case of the TSHR, autoAbs directed against 
most of the regions on the surface of the protein will have no pathologic consequences. 
Whereas if Abs occur against some discrete domain(s) of the receptor, they will provoke 
hyperthyroidism or hypothyroidism. Thus, the localization of the epitopes recognized by 
anti-TSHR Abs distinguishes patients with Graves’ disease from euthyroid subjects (Atger, 
1999).  
The Second possibility is that these autoAbs may even be directed against the same 
conformational epitope, but their molecular characteristics may differ. This indeed was 
found by Latrofa et al in Graves’ disease as well (Latrofa, 2004). Thus, these autoAbs in 
healthy subjects may be the precursors of the more potent SSc-associated autoAbs and  that 
an antigen driven process in genetically susceptible individuals leads to affinity maturation 
and IgG class switching of these naturally occurring autoAbs, which in turn, would become 
pathogenic and disease-specific when determined by functional assay (Latrofa, 2004). 
Thereby, the occurrence of pathogenic rather than non-pathogenic Abs in different subjects 
may be due either to their genetic background or to an encounter with a cross-reactive 
antigen (Guilbert, 1982; Tron, 1989; Coutinho, 1995). 
Noteworthy, AutoAbs from SSc sera induced neither col1a1 nor col III in our study 
(data not shown). It is possible that SSc-IgG could indirectly induce collagen expression 
via the imbalance between pro and antifibrotic TGFβ isoforms or via TGFβ1 itself. In 
addition, it is known that fibroblast activation in SSc may be a result of stimulation by 
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autocrine TGFβ signaling (Ihn, 2008). Likewise, tgfβ1 induced by SSc-IgG could activate 
autocrine TGFβ signaling in VSMCs and induce collagen deposition.  
We next immunoprecipitate PDGFR by IgG from SSc and controls to verify if the 
autoAbs that we found are the stimulatory anti-PDGFR Abs previously described. Both 
control and SSc patients immunoprecipitated the PDGFR, but the SSc-IgG significantly 
immunoprecipitate more PDGFR than control ones (Figure 12, page 55). However, the use 
of AG1296, a specific inhibitor of the PDGFR kinases did not block these IgG-induced 
ERK phosphorylations, despite effectively blocking these signals in PDGF-stimulated cells 
(Figure 13, page 57). Taken together, these findings indicate two possibilities. The first 
possibilty is that SSc-IgG activity on VSMCs is not mediated through PDGFR. This open 
the door for lots of other alternative explanations, for example, the SSc-IgG effect in our 
report could be mediated through the TGFβ receptor itself. It is well documented that in 
addition to the effects on Smad phosphorylation, TGFβ can signal via Ras and Rac proteins 
and activate certain MAP kinases including ERK 1 and 2 (Engel, 1999; Park, 2002). One 
study reported that in this pathway Ras/MEK/ERK potentiates CTGF gene expression in 
fibroblasts. Thus, the TGFβ induction of Ras/MEK/ERK seems to be profibrotic (Leask, 
3003). Although, SSc-IgG effect in our study could be mediated through this signaling 
pathway, there are lots of other receptor in literature could explain the SSc-IgG effects 
noticed in our study. Thus the use of modern and more comprehensive mass sperctrometry 
analysis (ms/ms) to identify the interactions between SSc-IgG and their specific receptor 
will be a more convenient and time saving method than approaching pharmacologically 
each of the possible receptors that may be involved.  
The second possibility is that SSc-IgG effects are mediated through PDGFR; 
however, this effect is independent of the tyrosine kinase phosphorylation of the PDGFR. 
Similar apparently tyrosine kinase-independent activities by PDGF have been reported. A 
study demonstrated that erg-1 by PDGF occurs in the absence of tyrosine kinase activity. 
While another found that, the inhibition of tyrosine kinase activity does not affect the 
increase in GaG chain elongation that is induced by PDGF. Such results suggest the 
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existence of PDGF signaling pathways that operate independently from PDGFR tyrosine 
kinase (Mundschau, 1994; Schonherr, 1997). Thus, in our study, PDGFR knockdown 
experiment is eagerly awaited in order to conclusively verify the involvement of the 
PDGFR in the effects of SSc antibodies. 
4.1 PDGFR stimulatory autoAbs in SSc: lessons learned and 
outcomes 
As mentioned earlier, autoAbs against PDGFRs were first reported by Baroni et al 
(Baroni, 2006). They demonstrated that sera from patients with SSc stimulates PDGFR-
positive fibroblasts, but not PDGFR-negative cells, to produce ROS and to activate Ha-Ras 
ERK1/2 signaling in normal fibroblasts, resulting in the expression of collagen and α-
smooth muscle actin. They also reported that sera IgG from patients with SLE or healthy 
control individuals did not stimulate fibroblasts to produce ROS. This study has not been 
replicated and many recent reports could not show the existence of these stimulatory anti- 
PDGFR Abs. Among these, the group of Classen et al, they purified immunoglobulins from 
37 SSc patients and tested PDGFR activation by these Abs using four different bioassays, 
i.e., cell proliferation, ROS production, signal transduction, and receptor phosphorylation. 
They showed that IgGs from patients with SSc had little effect on PDGFR signaling, 
including the proliferation of fibroblasts and PDGFRα phosphorylation (Classen, 2009). 
Whereas, another group reported that purified IgG from patients with SSc exhibited no 
agonist activity in a cell-based PDGFRα phosphorylation assay, and did not stimulate a 
mitogenic response or MAPK activation in a PDGFRα-expressing cell line (Loizos, 2009). 
Moreover, the same study using electrochemiluminescence binding assay showed that sera 
samples from normal individuals and SSc patients could bind to PDGFRs (Loizos, 2009). 
Similarly, using non-bioactive assays in Balada et al study anti-PDGFRα Abs were detected 
in sera from normal controls and SSc patients as well (Balada, 2008). Furthermore, two 
recent studies reported that these anti-PDGFR Abs are not specific to SSc since they have 
been found in extensive chronic graft-versus-host disease (ecGVHD), a disease with SSc-
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like clinical manifestation (Svegliati, 2007) and in patients with SLE (Kurasawa, 2010). 
The findings arising from these studies raise the question as whether these agonistic 
autoAbs to PDGFR in SSc exist or whether experimental variations play a role in these 
variant results. 
There are possible scenarios highlighted by Baroni et al group to clarify variations 
between their study and the above ones. First, they explained that the IgG purification 
process should involve size-exclusion chromatography, which removes small molecules. 
This step is essential to remove trace amounts of contaminating cytokines such as PDGF or 
TGF. Absence of this step may lead to misleading results (Classen, 2009; Gabrielli, 2009; 
Loizos, 2009). Second, the use of inconvenient cell lines that have low levels of cell surface 
PDGFR. Such cells are perfectly suitable for the detection of PDGF biological activity, but 
they may be not able to respond to low-affinity IgG due to competition by the Fc receptor 
(Classen, 2009; Gabrielli, 2009; Loizos, 2009). Third, the epitope recognized by these 
autoAbs is a conformational structure, recognized only in its native configuration. 
Difference in the PDGFR conformation in experiments could account for the differences in 
the results of studies. 
However, these explanations are unlikely in our study because the IgG purification 
steps involved a concentrating additional step to exclude contaminants. In addition, IgG 
purification process was done according to protocol provided from Baroni et al group to 
overcome the IgG sensitivity and instability described by them (unpublished observations). 
Although, we used VSMCs, not fibroblast, these cells are responsive to PDGF and express 
enormous amount of PDGFR that will reduce the chance for competition by Fc receptor 
(Lindqvist, 2001). Moreover, VSMCs were stayed in serum free media for two days to 
ensure quiescence. RTKs maintain in an inactive configuration in quiescent cells, which is 
suitable for these Abs binding (Schlessinger, 2000; Blume-Jensen, 2001; Schlessinger, 
2003).  
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In spite of that, so far we have been unable to prove that effects noticed in VSMCs 
in this study are mediated by PDGFR. Indeed, we also found autoAbs in some healthy 
control as well, and these autoAbs seem to be present in most, but not all, SSc patients. The 
autoAbs in this study are not a specific hallmark for SSc; however, they have a critical role 
in the fibrotic process via affecting TGFβ gene expressions. 
4.2 Conclusion and Perspectives 
In conclusion, we have identified, for the first time, autoAbs to VSMCs in patient 
with SSc, which provide a novel link between B cell mediated antibody production, 
vascular alteration and fibrosis in SSc. They appear to upregulate the profibrotic tgfb1 gene, 
and downregulate the antifibrotic tgfb2 gene, creating imbalance between fibrotic genes in 
favour of fibrosis. Although they do bind to the PDGFR of VSMCs, and although ERK 
phosphorylation is upregulated by the SSc-IgG, we could not prove that these effects are 
mediated by the PDGFR. Thus, the next step will be to clarify the involvement of the 
PDGFR by PDGFR knockdown experiments and/or pharmacological approaches to 
identify the SSc-Abs bound receptor. This step will explain part of the cause of 
vasculopathy in SSc and open the door for new therapeutic targets in treating the disease. 
Moreover, the existence of these antibodies should be replicated in larger number of 
patients and from other population. 
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